258 related articles for article (PubMed ID: 15743023)
1. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
2. The use of octreotide in the treatment of medullary thyroid carcinoma.
Frank-Raue K; Ziegler R; Raue F
Horm Metab Res Suppl; 1993; 27():44-7. PubMed ID: 8330871
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide].
Frank-Raue K; Raue F; Ziegler R
Med Klin (Munich); 1995 Feb; 90(2):63-6. PubMed ID: 7708002
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
[TBL] [Abstract][Full Text] [Related]
5. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
Díez JJ; Iglesias P
J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
[TBL] [Abstract][Full Text] [Related]
8. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
10. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
11. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
[TBL] [Abstract][Full Text] [Related]
12. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
13. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia.
Geelhoed GW; Bass BL; Mertz SL; Becker KL
Surgery; 1986 Dec; 100(6):962-70. PubMed ID: 2431492
[TBL] [Abstract][Full Text] [Related]
15. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
[TBL] [Abstract][Full Text] [Related]
16. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
17. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
Buscombe JR; Caplin ME; Hilson AJ
J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
[TBL] [Abstract][Full Text] [Related]
19. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.
Libroia A; Verga U; Di Sacco G; Piolini M; Muratori F
Henry Ford Hosp Med J; 1989; 37(3-4):151-3. PubMed ID: 2576951
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
Baudin E; Droz JP; Paz-Ares L; van Oosterom AT; Cullell-Young M; Schlumberger M
Am J Clin Oncol; 2010 Feb; 33(1):83-8. PubMed ID: 19704366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
